Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOX-C89
- Development stage
- Preclinical
- Lead developer
- TME Pharma
- Modality
- Spiegelmers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Topical
01
Overview
NOX-C89 is a **Spiegelmer** (mirror-image oligonucleotide aptamer) that **binds and neutralizes calcitonin gene-related peptide (CGRP)**, a neuropeptide implicated in vasodilatation and neurogenic inflammation particularly associated with primary headaches such as migraine. Mechanistically, NOX-C89 acts by **sequestering free CGRP**, thereby preventing its interaction with CGRP receptors on blood vessels, which reduces vasodilatory responses and can diminish neurogenic inflammation. Additionally, NOX-C89 may partly inhibit CGRP release from peripheral nerves. The molecule is approximately 14 kDa in size, and preclinical studies have shown activity in reducing meningeal blood flow and CGRP release in animal models. NOX-C89 is a variant of the earlier CGRP-binding Spiegelmer STAR-F12. Development has primarily been aimed at neurological disorders—especially migraine and headache—by targeting the pathophysiological release and action of CGRP[1][9][14].
- Other names
- Spiegelmer NOX-C89
02
Targets
CGRP (Calcitonin gene-related peptide)
Beyond the preview
Go deeper on NOX-C89.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOX-C89.